As of 2025-07-05, the EV/EBITDA ratio of Vanda Pharmaceuticals Inc (VNDA) is -4.57. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VNDA's latest enterprise value is 185.96 mil USD. VNDA's TTM EBITDA according to its financial statements is -40.73 mil USD. Dividing these 2 quantities gives us the above VNDA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.6x - 11.4x | 9.2x |
| Forward P/E multiples | 12.0x - 17.2x | 12.1x |
| Fair Price | (6.47) - (6.04) | (5.55) |
| Upside | -230.1% - -221.5% | -211.6% |
| Date | EV/EBITDA |
| 2025-07-03 | -4.57 |
| 2025-07-02 | -4.45 |
| 2025-07-01 | -4.15 |
| 2025-06-30 | -4.20 |
| 2025-06-27 | -4.29 |
| 2025-06-26 | -4.35 |
| 2025-06-25 | -4.05 |
| 2025-06-24 | -3.89 |
| 2025-06-23 | -3.84 |
| 2025-06-20 | -3.90 |
| 2025-06-18 | -3.93 |
| 2025-06-17 | -3.87 |
| 2025-06-16 | -4.00 |
| 2025-06-13 | -3.90 |
| 2025-06-12 | -4.07 |
| 2025-06-11 | -4.00 |
| 2025-06-10 | -4.12 |
| 2025-06-09 | -4.02 |
| 2025-06-06 | -4.05 |
| 2025-06-05 | -3.73 |
| 2025-06-04 | -3.80 |
| 2025-06-03 | -3.73 |
| 2025-06-02 | -3.60 |
| 2025-05-30 | -3.65 |
| 2025-05-29 | -3.73 |
| 2025-05-28 | -3.61 |
| 2025-05-27 | -3.64 |
| 2025-05-23 | -3.64 |
| 2025-05-22 | -3.51 |
| 2025-05-21 | -3.63 |
| 2025-05-20 | -3.80 |
| 2025-05-19 | -3.61 |
| 2025-05-16 | -3.39 |
| 2025-05-15 | -3.06 |
| 2025-05-14 | -3.05 |
| 2025-05-13 | -3.13 |
| 2025-05-12 | -3.21 |
| 2025-05-09 | -3.09 |
| 2025-05-08 | -3.48 |
| 2025-05-07 | -3.71 |
| 2025-05-06 | -3.70 |
| 2025-05-05 | -4.02 |
| 2025-05-02 | -3.99 |
| 2025-05-01 | -3.80 |
| 2025-04-30 | -3.90 |
| 2025-04-29 | -3.78 |
| 2025-04-28 | -3.60 |
| 2025-04-25 | -3.52 |
| 2025-04-24 | -3.61 |
| 2025-04-23 | -3.64 |